TY  - JOUR

T1  - Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial

PY  - -0001/11/30

AU  - Goodyear CS

AU  - Patel A

AU  - Barnes E

AU  - willicombe M

AU  - Siebert S

AU  - de Silva TI

AU  - Snowden JA

AU  - Lim S

AU  - Bowden S

AU  - Billingham LJ

AU  - Richter AG et al

ED  - 

Y2  - 2025/03/13

ER  -